Oluyemi Okupe Sells 23,090 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 23,090 shares of the stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80. Following the sale, the chief financial officer directly owned 94,333 shares in the company, valued at approximately $3,369,574.76. The trade was a 19.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total value of $853,513.47.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.
• On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.13, for a total transaction of $662,250.96.
• On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.72, for a total transaction of $669,263.40.
• On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.20, for a total value of $5,117,000.00.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded down $0.26 during mid-day trading on Tuesday, reaching $34.79. 9,438,031 shares of the stock traded hands, compared to its average volume of 30,638,605. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The business has a 50-day moving average of $41.45 and a 200 day moving average of $48.33. The stock has a market capitalization of $7.92 billion, a PE ratio of 64.42, a PEG ratio of 7.03 and a beta of 2.41. Hims & Hers Health, Inc. has a fifty-two week low of $23.97 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. During the same quarter last year, the company earned $0.32 earnings per share. Hims & Hers Health’s quarterly revenue was up 49.2% on a year-over-year basis. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has authorized a stock buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter worth approximately $26,000. Quent Capital LLC acquired a new position in Hims & Hers Health during the third quarter worth $28,000. Binnacle Investments Inc acquired a new position in Hims & Hers Health during the third quarter worth $28,000. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the second quarter valued at $29,000. Finally, Bessemer Group Inc. grew its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HIMS has been the topic of a number of analyst reports. Leerink Partnrs upgraded Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Bank of America boosted their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research report on Tuesday, November 4th. KeyCorp started coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Finally, Barclays initiated coverage on shares of Hims & Hers Health in a research note on Monday, December 8th. They set an “overweight” rating and a $48.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $45.50.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.